OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - GENMAB | Real-time Boerse Frankfurt Warrants 10:31:26 2024-06-27 am EDT | ||
| 5.79 EUR | +3.95% |
|
| Current month | +58.24% | ||
| 1 month | +41.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 5.79 | +3.95% |
| 24-06-26 | 5.57 | +3.92% |
| 24-06-25 | 5.36 | +1.13% |
| 24-06-24 | 5.3 | -1.30% |
| 24-06-21 | 5.37 | -2.36% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 10:31 am EDT
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW9WDL |
| ISIN | DE000SW9WDL7 |
| Date issued | 2024-05-03 |
| Strike | 2,214 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.14 € |
|---|---|
| Lowest since issue | 1.91 € |
| Spread | 0.03 € |
| Spread % | 0.52% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,791
DKK
Average target price
2,464
DKK
Spread / Average Target
+37.58%
- Stock Market
- Certificates
- Certificat
